|
Feb 26
|
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
|
|
Jan 9
|
Biotech Is Ripe for M&A. These May Be the Next Acquisition Targets.
|
|
Jan 2
|
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
|
|
Dec 23
|
With 85% ownership of the shares, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is heavily dominated by institutional owners
|
|
Dec 19
|
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 10
|
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
|
|
Dec 5
|
12 Most Promising Stocks to Buy According to Hedge Funds
|
|
Dec 4
|
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
|
|
Nov 7
|
Syndax Announces Participation at Stifel Healthcare Conference
|
|
Nov 7
|
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Could Be 49% Below Their Intrinsic Value Estimate
|
|
Nov 4
|
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
|
|
Nov 3
|
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
Nov 3
|
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Syndax Pharmaceuticals Inc (SNDX) Reports Q3 2023 Financial Results
|
|
Nov 2
|
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
|
|
Nov 2
|
Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
|
|
Nov 2
|
Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
|
|
May 24
|
Syndax Announces Participation at Two Upcoming Investor Conferences
|